Mira Pharmaceuticals, Inc. · NASDAQ:MIRA

Mira Pharmaceuticals — Investor Presentation (April 2026)

56 slides from Mira Pharmaceuticals's investor presentation, April 2026

1. Slide 1: Investor Presentation | Nasdaq: MIRA

   NASDAQ: MIRA April 2026 ©2023 MIRA Pharmaceuticals, Inc. All Rights Reserved. Investor Presentation | Nasdaq: MIRA

2. Slide 2: Management

   Management Erez Aminov Itzchak Angel, PhD Chief Executive Officer & Executive Chairman Chief Scientific Advisor ► Biotechnology executive with a track record of advancing drug candidates from preclinical ► Over 40 years of experience in guiding medical, pharmaceutical, drug, and development through

3. Slide 3: Corporate Overview

   Corporate Overview We are MIRA Pharmaceuticals— advancing a differentiated pipeline of oral therapies for neurologic, neuropsychiatric, and metabolic disorders. Built on safety and efficacy, our programs target high-value markets with significant unmet need and strong clinical demand. Our pipeline i

4. Slide 4: Our Pipeline

   Our Pipeline Indications Pre-Clinical Phase-I Phase-II Chemo-Induced Peripheral Ketamir-2 Neuropathy (CIPN) Mira-55 Inflammatory Pain Obesity SKNY-1 Smoking Cessation Investor Presentation | Nasdaq: MIRA 3

5. Slide 5: Ketamir-2: A Novel Oral Approach to Treating Neuropathic Pain

   Ketamir-2: A Novel Oral Approach to Treating Neuropathic Pain An advanced ketamine analog with fewer side effects, better safety, and clinical-stage momentum. What is Ketamir-2? • A next-generation oral ketamine analog with improved bioavailability, selectivity, and safety profile, specifically engi

6. Slide 6: Neuropathic Pain: High Prevalence, Low Satisfaction, and Urgent Demand

   Key Therapeutic Area Neuropathic Pain: High Prevalence, Low Satisfaction, and Urgent Demand An underserved patient population where existing treatments fall short — and the risk of addiction runs high. • Widespread and Costly Neuropathic pain affects 7–10% of the population globally, often linked to

7. Slide 7: TRD & PTSD: High Prevalence, Limited Options, and Urgent Demand

   Key Therapeutic Area Treatment Resistance Depression (TRD) & Post-Traumatic Stress Disorder (PTSD): High Prevalence, Limited Options, and Urgent Demand An underserved patient population where existing treatments fall short — and safe, effective options remain scarce. Widespread and Costly: • TRD aff

8. Slide 8: Ketamir-2: CMC

   Ketamir-2: CMC Simple and scalable process for drug substance and drug product production. Drug Substance Manufacturing Process • Simple, high yield drug substance synthesis • Source for Starting Material of high quality established and approved. • No impurities over 0.10% originated from Starting m

9. Slide 9: Ketamir-2: Pharmacology Precision Targeting at the NMDA Receptor

   Ketamir-2: Pharmacology Precision Targeting at the NMDA Receptor — Without the Collateral Effects A novel oral NMDA antagonist with selective PCP-site binding and none of ketamine’s psychomimetic baggage. • Low-Affinity, Highly Selective NMDA Modulation Ketamir-2 acts as a low- affinity antagonist a

10. Slide 10: Ketamir-2: CNS Differentiation Without Hyperlocomotion or Euphoria

    Ketamir-2: Pharmacology CNS Differentiation Without Hyperlocomotion or Euphoria Unlike ketamine, Ketamir-2 does not induce hyperactivity — a key signal of reduced psychomimetic liability. • Clinical locomotor activity testing confirms no increase in spontaneous movement with oral or injected Ketamir

11. Slide 11: Validated Rodent Model for Neuropathic Pain Evaluation

    Ketamir-2: Pharmacology Validated Rodent Model for Neuropathic Pain Evaluation The Chung Model simulates clinically relevant nerve injury to assess therapeutic effects in neuropathic pain. • Surgical Procedure- Ligation of L5 and L6 spinal nerves induces partial nerve injury, mimicking human neuropa

12. Slide 12: Ketamir-2 Demonstrates Potent Pain Relief in Validated Animal Models

    Ketamir-2 Demonstrates Potent Pain Relief in Validated Animal Models Effective across sexes, models, and doses — with statistically significant reversal of neuropathic pain. • Chung Model (Rats): - Male and female rats with spinal nerve ligation • Ketamir-2 produced dose-dependent reversal of allody

13. Slide 13: PTX-Induced Neuropathy Model in Mice

    Ketamir-2: Pharmacology PTX-Induced Neuropathy Model in Mice Validates Mechanical Allodynia Development A chemotherapy-induced pain model mimicking clinical neuropathic symptoms—enabling evaluation of therapeutic interventions in a controlled, time-specific window. • Model Overview: Paclitaxel (PTX)

14. Slide 14: Ketamir-2 Produces Dose-Dependent Pain Reversal in Mice Post-PTX Treatment

    Ketamir-2 Produces Dose-Dependent Pain Reversal in Mice Post-PTX Treatment Following paclitaxel-induced neuropathy, Ketamir-2 demonstrated significant and progressive pain relief starting at 30mg/kg PO, with complete reversal to baseline levels at 100–300mg/kg—outperforming Gabapentin in this valida

15. Slide 15: Antidepressant-Like Behavior Without Stimulant Effects

    Ketamir-2: Pharmacology Promotes Antidepressant-Like Behavior Without Stimulant Effects Demonstrates increased movement and velocity without hyperactivity — mirroring classical antidepressant responses in the Open Field Test • Open Field Test is a validated model for screening antidepressant and anx

16. Slide 16: Ketamir-2 Shows Anxiolytic-Like Effects in Elevated Plus Maze

    Ketamir-2 Shows Anxiolytic-Like Effects in Elevated Plus Maze Demonstrates increased movement and time in center — consistent with reduced anxiety and enhanced exploratory behavior • Elevated Plus Maze is a classical assay used to assess anxiolytic and antidepressant activity based on exploratory be

17. Slide 17: ADME Shows Superior Oral Bioavailability and Brain Penetration Potential

    Ketamir-2: ADME Shows Superior Oral Bioavailability and Brain Penetration Potential Not a substrate of P-gp efflux transporter — enabling improved absorption and CNS exposure compared to ketamine • Caco-2 assay results confirm Ketamir-2 is not a substrate for P- glycoprotein (P-gp), unlike ketamine.

18. Slide 18: Ketamir-2: ADME

    Ketamir-2: ADME Rapidly absorbed and metabolized to active Nor-Ketamir • Ketamir-2 pamoate in a specific 2-hydroxypropyl-beta- cyclodextrin(HP-β-CD formulation is rapidly absorbed • It is metabolized to the Nor-Ketamir metabolite with has similar pcp-site activity and selectivity as Ketamir-2 • Nor-

19. Slide 19: Ketamir-2: ADME

    Ketamir-2: ADME In Rats, females have higher levels of Ketamir-2 and Nor-Ketamir. Not seen in dogs. • Female rats have a higher level of Ketamir-2 and Nor-Ketamir than males (Cmax of 127 and 1620 ng/ml Ketamir-2, and 1930 and 3790 ng/ml Nor-Ketamir, for males and females respectively) • No kinetic s

20. Slide 20: Ketamir-2: Toxicology

    Ketamir-2: Toxicology Excellent safety and toxicology profile • Ketamir-2 was found to be highly selective across a broad receptor, enzymes and channels panel • Non-mutagenic, non-genotoxic in standard assays • Not neurotoxic in NMDA specific neurotoxicity study • NOAELs: 300 mg/kg/day in rats; 200

21. Slide 21: Ketamir-2 Preclinical Summary

    Ketamir-2 Preclinical Summary: Clinical Profile Supports Further Development Mechanistically selective, orally bioavailable, and non-genotoxic — with consistent activity across models of depression, anxiety, and neuropathic pain Chemistry & Formulation (CMC) • Ketamir-2 is a stable crystalline analo

22. Slide 22: Ketamir-2: Clinical

    Ketamir-2: Clinical Completed phase 1 study demonstrating favorable safety and tolerability across doses up to 600mg; Advancing toward Phase 2a Design: • Randomized, double-blind, placebo-controlled, single-center Phase | trial (MIRA- 001) assessing safety, tolerability, and pharmacokinetics of oral

23. Slide 23: Phase-I Results: Human Plasma Levels of Ketamir-2 and Nor-Ketamir

    Phase-I Results: Human Plasma Levels of Ketamir-2 and Nor-Ketamir Ketamir-2 Nor-Ketamir Investor Presentation | Nasdaq: MIRA 22

24. Slide 24: Phase-I Results: Key PK Parameters

    Phase-I Results: Key PK Parameters Ketamir-2 Nor-Ketamir Ketamir-2 Nor-Ketamir Ketamir-2 Nor-Ketamir Dose Cmax (ng/ml) Tmax (h) T1/2 (h) (mg/day) 50 22.7±2.72 73.9±2.1 1±0.2 1.1±0.2 2.1±.6 8.5±0.8 150 59.6±15.8 210.0±18.9 1.1±0.3 1.7±0.3 2.0±0.5 6.5±1.1 300 111.6±18.0 349±19.6 1.6±0.2 1.9±0.3 3.6±0.

25. Slide 25: Phase-I Results: Conclusions

    Phase-I Results: Conclusions • No safety concerns Absorption of Ketamir-2 in human subjects is rapid and dose-proportional with relatively short half-life (2-5 hours) • Metabolism into nor-Ketamir is rapid, with similar Tmax of the parent compound and the metabolite • Plasma levels (Cmax) of nor-Ket

26. Slide 26: Clinical Development Timeline and Upcoming Milestones

    Ketamir-2: Clinical Clinical Development Timeline and Upcoming Milestones Q1 2026 Q2 2026 Q2 2027 Phase 1 Completed Phase 2a Initiation (CIPN) Phase 2/3 Investor Presentation | Nasdaq: MIRA 25

27. Slide 27: Ketamir-2: Topical Formulation

    Ketamir-2: Topical Formulation Topical hydrophobic formulation for Ketamir-2 were developed • Ketamir-2 was developed in three different oily formulations for topical administration • Formulations B and C had the best In Vitro Release testing (IVRT) values Investor Presentation | Nasdaq: MIRA 26

28. Slide 28: Ketamir-2: Topical Formulation

    Ketamir-2: Topical Formulation Topical hydrophobic formulation is effective in reducing pain behavior in the formalin test in mice • Ketamir-2 cream in two formulations was applied to mice paws 30 minutes before and just prior to formalin administration into the paw • Formalin administration produce

29. Slide 29: Ketamir-2: Topical Formulation

    Ketamir-2: Topical Formulation Topical hydrophobic formulation #C is effective in reducing pain behavior in the formalin test in mice. Efficacy on both early and late phases and in two tests with better or similar to injected morphine Paw Licking Paw Lifting Investor Presentation | Nasdaq: MIRA 28

30. Slide 30: Ketamir-2: Topical Formulation

    Ketamir-2: Topical Formulation Topical hydrophobic formulation #C is effective in reducing pain behavior in the formalin test in mice – view of the whole-time profile Investor Presentation | Nasdaq: MIRA 29

31. Slide 31: Ketamir-2 Development Pathway Toward Phase IIa

    Ketamir-2 Development Pathway Toward Phase IIa A strong foundation from clinical and Phase 1 data supports rapid advancement into neuropathy patients. Market Opportunity (global pain): CIPN (chemotherapy-induced peripheral neuropathy): • Pain therapeutics market expected to exceed $120B • CIPN occur

32. Slide 32: Development Pathway Toward Phase IIa in CIPN

    Ketamir-2 Development Pathway Toward Phase IIa in CIPN A strong foundation from clinical and Phase 1 data supports rapid advancement into neuropathy patients. FDA IND USA IND obtained enabling Phase IIa trials Phase 1 Mira-001 completed Phase IIa CIPN study initiation Q2 2026 Safety Endpoints AE/SAE

33. Slide 33: Strategic Partnership Opportunity: Ketamir-2

    Strategic Partnership Opportunity: Ketamir-2 Objective License, co-develop, or acquire Ketamir-2 to accelerate development in CIPN, neuropathic pain and unlock expansion across depression, PTSD and topical pain treatment. Partner Value Access to > $120B global pain therapeutics market First-in-class

34. Slide 34: What is MIRA-55?

    What is MIRA-55? Key Differentiating Factors THC MIRA-55 • Schedule 1, which means no • Pure Synthetic accepted medical purpose • Based on animal model studies, • Negative side effects better side effect profile (e.g. decreased anxiety across the dose • Legal/regulatory hurdles range, improved rathe

35. Slide 35: MIRA-55 Reduces Inflammatory Pain

    MIRA-55 Reduces Inflammatory Pain In the formalin test, rats treated with MIRA-55 had a lower sensitivity to pressure — a clear sign of reduced inflammatory pain • Validated Model: The formalin test is a known inflammatory test in rodents • Improved Behavior: MIRA-55 significantly reduced the sensit

36. Slide 36: MIRA-55 Reduces Anxiety Without Sedation or Intoxication

    MIRA-55 Reduces Anxiety Without Sedation or Intoxication In the Elevated Plus Maze, mice treated with MIRA-55 spent more time exploring open areas — a clear sign of reduced anxiety — without showing signs of sedation. • Validated Model: The Elevated Plus Maze tests anxiety by measuring time spent in

37. Slide 37: MIRA-55 Shows Significant Pain Relief in Thermal Sensitivity Model

    MIRA-55 Shows Significant Pain Relief in Thermal Sensitivity Model Mice treated with MIRA-55 took longer to react to heat — a clear sign of reduced pain sensitivity compared to placebo. • Validated Model: Mice were placed on a heated plate and observed for paw-lift response time • Reduced Pain Sensi

38. Slide 38: MIRA-55 Enhances Memory Recall in Contextual Fear Conditioning

    MIRA-55 Enhances Memory Recall in Contextual Fear Conditioning In a validated cognitive model, MIRA-55 significantly improved memory performance — suggesting enhanced associative learning with no sedative tradeoffs. • Model Overview: Mice were trained to associate a chamber with a mild shock; freezi

39. Slide 39: Regulatory Pathway to Commercialization

    Regulatory Pathway to Commercialization To develop, MIRA-55 as a commercialization asset, we are proceeding on a well-established regulatory pathway designed to establish its safety and efficacy 1 2 Clinical Testing Clinical Trials Focus on clinical testing Clinical testing and trials including gene

40. Slide 40: A Next-Generation Approach to Obesity & Smoking Cessation

    A Next-Generation Approach to Obesity & Smoking Cessation Unlocking metabolic and behavioral health innovation through SKNY-1 • Oral small molecule THCV analog with non-controlled status • Multi-mechanistic profile: CB1 antagonist, CB2 partial agonist, MAO-B inhibition Designed to address obesity, s

41. Slide 41: The Endocannabinoid System: A Master Regulator of Metabolism and Craving

    The Endocannabinoid System: A Master Regulator of Metabolism and Craving CB1 and CB2 receptors influence appetite, insulin sensitivity, lipid metabolism, and reward — making them ideal targets for obesity and addiction. • CB1 and CB2 receptors are found throughout the brain Appetite Body • Insulin R

42. Slide 42: Multi-Target Mechanism to Address Complex Metabolic and Behavioral Conditions

    Multi-Target Mechanism to Address Complex Metabolic and Behavioral Conditions SKNY-1’s unique combination of activities enables broad therapeutic coverage across obesity, addiction, and metabolic dysregulation. • CB1 Antagonism (biased) : Reduces appetite, body weight, and craving by dampening centr

43. Slide 43: SKNY-1: A Low Potency, Biased CB1 Antagonist

    SKNY-1: A Low Potency, Biased CB1 Antagonist SKNY-1 exhibits pathway-selective CB1 modulation, offering a differentiated mechanism versus traditional cannabinoid compounds. • No β-arrestin activation: SKNY-1 does not stimulate β-arrestin pathways, reducing potential side effects. • G-Protein activit

44. Slide 44: SKNY-1: A Low Potency, Biased CB1 Antagonist

    SKNY-1: A Low Potency, Biased CB1 Antagonist SKNY-1 blocks CB1-agonist induced anxiogenic effect in Zebrafish, while Rimonabant potentiates it • CB1 antagonist activity: At high concentrations, the CB1 agonist CP-55940 induces anxiogenic activity in zebra fish, expressed as an increase in the time s

45. Slide 45: SKNY-1: Tackling Obesity with a Differentiated Mechanism

    SKNY-1: Tackling Obesity with a Differentiated Mechanism Designed to modulate appetite and metabolism without the psychiatric baggage of first-generation CB1 blockers. • Selective modulation of CB1 receptor without β-arrestin activation — may reduce CNS-related side effects • Demonstrates partial ag

46. Slide 46: Avoiding the Pitfalls of First-Generation CB1 Blockers

    Avoiding the Pitfalls of First-Generation CB1 Blockers Designed to retain metabolic benefit while minimizing psychiatric burden Earlier CB1 blockers like Rimonabant were effective in reducing weight and improving metabolic parameters — but failed due to CNS-related psychiatric side effects (e.g., de

47. Slide 47: MAO-B Inhibition: Enhancing Motivation and Reducing Craving

    MAO-B Inhibition: Enhancing Motivation and Reducing Craving SKNY-1 selectively and weakly inhibits MAO-B — supporting dopaminergic tone with minimal CNS risk. Low-Affinity, Selective MAO-B Inhibition: • SKNY-1 inhibits MAO-B (EC₅₀ ≈ 300 µM) with minimal effect on MAO-A (EC₅₀ > 1000 µM), avoiding off

48. Slide 48: Preclinical Profile of SKNY-1: Concentration-Dependent Pharmacology

    Preclinical Profile of SKNY-1: Concentration-Dependent Pharmacology SKNY-1 exhibits distinct activity across CB1, CB2, and MAO-B targets depending on dose level, supporting its role as a multifunctional, biased modulator. • CB2 Agonism: Strong activation at low concentrations (1– 10µM), with reduced

49. Slide 49: SKNY-1's Multi-Tissue Action

    SKNY-1’s Multi-Tissue Action: A Coordinated Strategy for Obesity and Addiction A single compound influencing central and peripheral targets — uniting metabolic, behavioral, and inflammatory control. • Brain: Modulates CB1 and inhibits MAO-B, impacting appetite regulation, reward signaling, and dopam

50. Slide 50: Obesity and Craving Model in Zebra Fish

    Obesity and Craving Model in Zebra Fish Body weight changes without muscle density changes • SKNY-1 was recently studied in an obesity and craving model in Zebra fish in collaboration with Pentagrit using MC4R strain -ObZebrafish [Ob42 Strain-mc4r(G894C) was used • Adult zebrafish have been exposed

51. Slide 51: Obesity and Craving Model in Zebra Fish

    Obesity and Craving Model in Zebra Fish Cholesterol regulation • At both studied doses, a marked decrease in cholesterol and LDL levels and a marked increase in HDL levels were observed. • These changes brought the respective levels towards wild-type levels  . Investor Presentation | Nasdaq: MIRA 5

52. Slide 52: Obesity and Craving Model in Zebra Fish

    Obesity and Craving Model in Zebra Fish Appetite and craving for food and nicotine regulation • Several parameters related to high calorie food and nicotine craving were evaluated. • A marked, dose dependent decrease of high calorie and nicotine craving was observed, with highly significant decrease

53. Slide 53: Advancing SKNY-1 Toward Strategic Partnership and Clinical Validation

    Advancing SKNY-1 Toward Strategic Partnership and Clinical Validation Differentiated science, druggable profile, and commercial opportunity converge in SKNY-1 • Highly differentiated THCV-analog small molecule with CB1/CB2/MAO-B selectivity Multi-mechanistic action addresses both metabolic and behav

54. Slide 54: Ketamir-2 IP Protection

    KETAMIR-2 IP PROTECTION Intellectual property protection for KETAMIR-2 • Worldwide patent protection is pending for Ketamir-2 and its therapeutic uses • WO 2024/191676 A1, “Antidepressant Compounds, Pharmaceutical Compositions, and Methods of Treating Depression and Other Disorders” • MIRA is the ex

55. Slide 55: Investment Highlights

    Investment Highlights KETAMIR-2 MIRA-55 SKNY-1 Ketamir-2 is a novel oral ketamine analog MIRA-55 is a THC analog designed to SKNY-1 is a THCV analog with CB1 antagonist, CB2 partial with improved bioavailability, CNS treat inflammatory pain, reduce anxiety, and enhance agonist, and MAO-B inhibition

56. Slide 56: Thank you.

    Thank you. mirapharmaceuticals.com Meeting Presentation

MIRA Pharmaceuticals — Investor Presentation (April 2026) on 6ix